Oncotarget

Research Papers:

Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus

Sarah L. Hulin-Curtis, James A. Davies, Rachel Jones, Emma Hudson, Louise Hanna, John D. Chester and Alan L. Parker _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:26328-26341. https://doi.org/10.18632/oncotarget.25242

Metrics: PDF 408 views  |   HTML 724 views  |   ?  


Abstract

Sarah L. Hulin-Curtis1, James A. Davies1, Rachel Jones2, Emma Hudson2, Louise Hanna2, John D. Chester1,2 and Alan L. Parker1

1Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK

2Velindre Cancer Centre, Whitchurch, Cardiff, CF14, 2TL, UK

Correspondence to:

Alan L. Parker, email: parkeral@cardiff.ac.uk

Keywords: histone deacetylase inhibitor; oncolytic adenovirus; cisplatin-resistance; ovarian cancer

Received: October 29, 2017     Accepted: April 07, 2018     Published: May 29, 2018

ABSTRACT

Ovarian cancer is often termed a silent killer due to the late onset of symptoms. Whilst patients initially respond to chemotherapy, they rapidly develop chemo-resistance. Oncolytic adenoviruses (OAds) are promising anti-cancer agents engineered to “hijack” the unique molecular machinery of cancer cells enabling tumour-selective viral replication. This allows spread to adjacent cells and amplification of oncolysis within the tumour. OAds represent an excellent opportunity for ovarian cancer therapy via intra-peritoneal delivery, however the efficacy of OAds thus far is limited. Here, we evaluate chromatin (histone) modification in chemo-resistant cells and its relationship to Ad efficacy (wild-type or oncolytic Ad). In contrast to cisplatin-sensitive A2780 cells that show an efficient reduction of cell viability by Ad in the presence of cisplatin, cisplatin-resistant A2780/cp70 cells show diminishing Ad-mediated reduction of cell viability with escalating doses of cisplatin. Histone deacetylase (HDAC)-2 and to a lesser extent HDAC1 were up-regulated in cisplatin-resistant but not cisplatin-sensitive cells. Cisplatin-resistant cells treated with a pan-HDAC inhibitor trichostatin A (TsA) significantly enhanced Ad-mediated reduction of cell viability in the presence of cisplatin. Cells treated with TsA alone did not reduce cell viability suggesting these findings are Ad-dependent. Thus, we identify HDAC inhibition as a potential means to sensitise cisplatin-resistant ovarian cancer cells to virotherapies, an observation that may offer improved outcomes for patients with late stage, chemotherapy-resistant ovarian cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 25242